Oxford Immunotec Announces Release of New National Tuberculosis Test Data and Screening Grant for High Risk Patients on World TB Day
OXFORD, United Kingdom and MARLBOROUGH, Mass., 2017-03-23 22:50 CET (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the release of national T-SPOT®.TBtest positivity rates within the United States and United Kingdom, as well as a grant to support TB screening for high risk patients.
Today, only active TB infections are reported to the Centers for Disease Control and Prevention in the U.S. and National Health Services in the U.K. Patients with latent TB infections far outnumber those with active TB disease, but consolidating test results from multiple sources makes this challenging to track.
Oxford Immunotec has compiled a unique data set of T-SPOT.TBtest results for both the United States and the United Kingdom through its Oxford Diagnostic Laboratories®’ testing services. This data provides a representative overview of the positivity rate of T-SPOT.TBtests in 2016 by state and region, and is shown in three heat maps:
- U.S. T-SPOT.TBtest positive rates by state
- U.K. T-SPOT.TBtest positive rates by region
- U.S. T-SPOT.TBtest positive rates by state for customers who serve patients at higher risk of developing active TB. (High risk populations in this data set include contact investigations, refugees, HIV patients and patients on immunosuppressive therapy.)
Further, the Company announced that they have provided a grant for tuberculosis screening to the Florida Department of Health – Hillsborough County. This grant will allow the Florida Department of Health to screen up to 250 additional high-risk patients on World TB Day.
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the T-SPOT.TBtest, which is used to test for tuberculosis infection. The T-SPOT.TBtest has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company’s third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA clearance. The T-SPOT.CMVtest and the T-SPOT.PRTtest are pipeline products as part of the Company’s fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Anomali, Inc.20.9.2018 16:01 | pressemeddelelse
Anomali Launches Comprehensive Threat Platform to Detect and Respond to Cyber Attacks
Anomali, Inc.20.9.2018 16:01 | pressemeddelelse
Anomali Announces Major Expansion of Threat Platform Partner Ecosystem
Taconic Biosciences20.9.2018 15:41 | pressemeddelelse
Taconic Biosciences Becomes the First Animal Model Provider on Federal General Services Administration
XBiotech Inc.20.9.2018 14:01 | pressemeddelelse
XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its Team
VistaJet Ltd20.9.2018 13:42 | pressemeddelelse
Vista Global Acquires XOJET, the Leading On Demand Business Aviation Company in North America With 43 Aircraft, Strengthening Its Global Presence With 115 Owned Business Jets
Erytech Pharma S.A.20.9.2018 07:31 | pressemeddelelse
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum